Literature DB >> 16177100

Nonobese diabetic mouse congenic analysis reveals chromosome 11 locus contributing to diabetes susceptibility, macrophage STAT5 dysfunction, and granulocyte-macrophage colony-stimulating factor overproduction.

Sally A Litherland1, Kristie M Grebe, Nicole S Belkin, Edward Paek, Jessica Elf, Mark Atkinson, Laurence Morel, Michael J Clare-Salzler, Marcia McDuffie.   

Abstract

Unstimulated monocytes of at-risk/type 1 diabetic humans and macrophages of the NOD mouse have markedly elevated autocrine GM-CSF production and persistent STAT5 phosphorylation. We analyzed the relationship between GM-CSF production and persistent STAT5 phosphorylation in NOD macrophages using reciprocal congenic mouse strains containing either diabetes-susceptible NOD (B6.NODC11), or diabetes-resistant C57L (NOD.LC11) loci on chromosome 11. These intervals contain the gene for GM-CSF (Csf2; 53.8 Mb) and those for STAT3, STAT5A, and STAT5B (Stat3, Stat5a, and Stat5b; 100.4-100.6 Mb). High GM-CSF production and persistent STAT5 phosphorylation in unactivated NOD macrophages can be linked to a region (44.9-55.7 Mb) containing the Csf2 gene, but not the Stat3/5a/5b genes. This locus, provisionally called Idd4.3, is upstream of the previously described Idd4.1 and Idd4.2 loci. Idd4.3 encodes an abundance of cytokine genes that use STAT5 in their macrophage activation signaling and contributes approximately 50% of the NOD.LC11 resistance to diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177100      PMCID: PMC2605964          DOI: 10.4049/jimmunol.175.7.4561

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Genetics of autoimmune diseases in humans and in animal models.

Authors:  Grant Morahan; Laurence Morel
Journal:  Curr Opin Immunol       Date:  2002-12       Impact factor: 7.486

2.  Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.

Authors:  M Kieslinger; I Woldman; R Moriggl; J Hofmann; J C Marine; J N Ihle; H Beug; T Decker
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

3.  Congenic mapping of the diabetogenic locus Idd4 to a 5.2-cM region of chromosome 11 in NOD mice: identification of two potential candidate subloci.

Authors:  Marsha Grattan; Qing-Sheng Mi; Craig Meagher; Terry L Delovitch
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

4.  Activation of a functionally distinct 80-kDa STAT5 isoform by IL-5 and GM-CSF in human eosinophils and neutrophils.

Authors:  E Caldenhoven; T B van Dijk; J A Raaijmakers; J W Lammers; L Koenderman; R P de Groot
Journal:  Mol Cell Biol Res Commun       Date:  1999-05

5.  Signal transduction activator of transcription 5 (STAT5) dysfunction in autoimmune monocytes and macrophages.

Authors:  S A Litherland; T X Xie; K M Grebe; A Davoodi-Semiromi; J Elf; N S Belkin; L L Moldawer; M J Clare-Salzler
Journal:  J Autoimmun       Date:  2005-03-23       Impact factor: 7.094

6.  Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.

Authors:  Kevin D Bunting; Heath L Bradley; Teresa S Hawley; Richard Moriggl; Brian P Sorrentino; James N Ihle
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

7.  Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation.

Authors:  Anne Lehtonen; Sampsa Matikainen; Minja Miettinen; Ilkka Julkunen
Journal:  J Leukoc Biol       Date:  2002-03       Impact factor: 4.962

8.  Myeloid differentiation of FdCP1 cells is dependent on Stat5 processing.

Authors:  F Piazza; J Valens; E Lagasse; C Schindler
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

Review 9.  GM-CSF in inflammation and autoimmunity.

Authors:  John A Hamilton
Journal:  Trends Immunol       Date:  2002-08       Impact factor: 16.687

10.  Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation.

Authors:  Chiara Berlato; Marco A Cassatella; Ichiko Kinjyo; Luana Gatto; Akihiko Yoshimura; Flavia Bazzoni
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

View more
  15 in total

Review 1.  Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes.

Authors:  John P Driver; Yi-Guang Chen; Clayton E Mathews
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 2.  Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease.

Authors:  John P Driver; David V Serreze; Yi-Guang Chen
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

3.  Over-expression of Stat5b confers protection against diabetes in the non-obese diabetic (NOD) mice via up-regulation of CD4(+)CD25(+) regulatory T cells.

Authors:  Yulan Jin; Sharad Purohit; Xueqin Chen; Bing Yi; Jin-Xiong She
Journal:  Biochem Biophys Res Commun       Date:  2012-07-10       Impact factor: 3.575

4.  NOD x 129.H2(g7) backcross delineates 129S1/SvImJ-derived genomic regions modulating type 1 diabetes development in mice.

Authors:  Edward H Leiter; Peter C Reifsnyder; Racheal Wallace; Renhua Li; Benjamin King; Gary C Churchill
Journal:  Diabetes       Date:  2009-03-31       Impact factor: 9.461

5.  Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells.

Authors:  Thomas Enzler; Silke Gillessen; Michael Dougan; James P Allison; Donna Neuberg; Darryl A Oble; Martin Mihm; Glenn Dranoff
Journal:  Blood       Date:  2007-05-04       Impact factor: 22.113

6.  Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes.

Authors:  Marcia McDuffie; Nelly A Maybee; Susanna R Keller; Brian K Stevens; James C Garmey; Margaret A Morris; Elizabeth Kropf; Claudia Rival; Kaiwen Ma; Jeffrey D Carter; Sarah A Tersey; Craig S Nunemaker; Jerry L Nadler
Journal:  Diabetes       Date:  2007-10-16       Impact factor: 9.461

7.  GM-CSF induces STAT5 binding at epigenetic regulatory sites within the Csf2 promoter of non-obese diabetic (NOD) mouse myeloid cells.

Authors:  F Seydel; E Garrigan; B Stutevoss; N Belkin; B Makadia; J Carter; J-D Shi; A Davoodi-Semiromi; M McDuffie; S A Litherland
Journal:  J Autoimmun       Date:  2008-10-21       Impact factor: 7.094

8.  Linking chronic infection and autoimmune diseases: Mycobacterium avium subspecies paratuberculosis, SLC11A1 polymorphisms and type-1 diabetes mellitus.

Authors:  Daniela Paccagnini; Lee Sieswerda; Valentina Rosu; Speranza Masala; Adolfo Pacifico; Maria Gazouli; John Ikonomopoulos; Niyaz Ahmed; Stefania Zanetti; Leonardo A Sechi
Journal:  PLoS One       Date:  2009-09-21       Impact factor: 3.240

9.  Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes.

Authors:  Bo Chen; Bing Yi; Rui Mao; Haitao Liu; Jinhua Wang; Ashok Sharma; Stephen Peiper; Warren J Leonard; Jin-Xiong She
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

10.  Slc11a1 enhances the autoimmune diabetogenic T-cell response by altering processing and presentation of pancreatic islet antigens.

Authors:  Yang D Dai; Idania G Marrero; Philippe Gros; Habib Zaghouani; Linda S Wicker; Eli E Sercarz
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.